Eltrombopag For Secondary Poor Graft Function Post Allogeneic Hematopoietic Stem Cell Transplantation
Status:
Unknown status
Trial end date:
2020-01-01
Target enrollment:
Participant gender:
Summary
To investigate the efficacy and safety for secondary poor graft function (PGF) post
allogeneic hematopoietic stem cell transplantation (allo-HSCT). The primary objective is the
hematologic response rate. Secondary objectives include: (1) incidence and severity of
adverse events; (2) overall survival (OS), and disease-free survival(DFS).
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University